# Case Report

# Endovascular implantation of covered stents in the extracranial carotid and vertebral arteries: Case series and review of the literature

Ali Alaraj, Adam Wallace, Sepideh Amin-Hanjani, Fady T Charbel, Victor Aletich

Department of Neurosurgery, University of Illinois at Chicago, College of Medicine, Chicago IL, USA

E-mail: \*Ali Alaraj - alaraj@uic.edu; Adam Wallace - adam.n.wallace@gmail.com, Sepideh Amin-Hanjani - hanjani@uic.edu, Fady T Charbel - fcharbel@uic.edu, Victor Aletich - valetich@uic.edu

\*Corresponding author

Received: 05 January 11 A

Accepted: 26 April 11

Published: 28 May 11

This article may be cited as: Alaraj A, Wallace A, Amin-Hanjani S, Charbel FT, Aletich V. Endovascular implantation of covered stents in the extracranial carotid and vertebral arteries: Case series and review of the literature. Surg Neurol Int 2011;2:67.

Available FREE in open access from: http://www.surgicalneurologyint.com/text.asp?2011/2/1/67/81725

Copyright: © 2011 Alaraj A. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

### Abstract

**Background:** Covered stents are used endovascularly to seal arterial wall defects while preserving vessel patency. This report describes our experience with the use of covered stents to treat cervical pathology, and a review of the literature in regards to this topic is presented.

**Case Description:** Two patients presenting with the carotid blowout syndrome and one patient with a vertebrojugular fistula were treated with covered stents. This allowed for preservation of the vessel and was a treatment alternative to cerebral bypass.

**Conclusion:** Covered stents provide a viable means of preserving the cervical vessels in selected patients; however, long-term follow-up is necessary to determine stent patency and permanency of hemostasis.

KeyWords: Covered stent, carotid blow-out, endovascular, vertebrojugular fistula



### **INTRODUCTION**

Covered stents consist of a synthetic material that either covers or is attached to a metallic stent to create a graft endoprosthesis. The covering excludes breaches to the integrity of the arterial wall, while preserving vessel patency. Covered stents have been used to treat aneurysms,<sup>[43,53,58]</sup> traumatic arterial injuries,<sup>[79,102,108]</sup> and arteriovenous fistulas (AVF)<sup>[43,79,102,108]</sup> of the axillary, subclavian, iliac, femoral, and popliteal arteries.

The emergence of neuroendovascular techniques offers an alternative treatment for patients in whom surgery is contraindicated. Advantages of an endovascular approach include: an easier access, less invasiveness, performance under local anesthesia, less post-procedural pain and disability, and less expense.<sup>[79]</sup> The Food and Drug Administration (FDA) has not approved the use of covered stents for neuroendovascular interventions; however, these devices offer a potentially less morbid alternative in the treatment of complex, extracranial disease where surgical options are limited. We describe our experience with the placement of covered stents in the treatment of the carotid blowout syndrome (CBS) and a vertebrojugular fistula (VJF). We also review the present literature regarding the use of covered stents in extracranial cerebral circulation.

### **CASE REPORTS**

The Institutional Review Board approval was obtained for the retrospective review of all extracranial neuroendovascular interventions between January 2006 and June 2009. Three patients treated with a covered

stent endoprosthesis were identified and their charts were reviewed. One patient was diagnosed with VJF. Two patients were diagnosed with CBS, one of whom was with bilateral CBS. The off-label use of the covered stent was disclosed in all cases, and informed consent was obtained for all procedures.

### Case 1

A 51-year-old woman presented with a ten-week history of persistent left-sided neck pain and pulsatile tinnitus. Cerebral angiography demonstrated a large, high-flow AVF originating from the left vertebral artery (VA) and draining into the internal jugular veins bilaterally [Figure 1a]. Retrograde flow from the right VA also supplied the fistula [Figure 1b]. Diffuse, advanced fibromuscular dysplasia was observed in the cervical segments of both the vertebral arteries and was the presumed underlying etiology. Flow measurements with quantitative magnetic resonance angiography (Q-MRA) using the Non-invasive Optimal Vessel Analysis (NOVA) software (VasSol Inc., Chicago, IL) demonstrated that the fistula was supplied by 744 ml / minute of antegrade flow through the left VA and 55 ml / minute of retrograde flow through the right VA.

Due to the complexity of the fistula, surgery and endovascular coiling were not feasible. Additionally, preservation of the VA was preferred given the presence of fibromuscular dysplasia. The procedure was performed under general anesthesia. Loading doses of intravenous Heparin (5000 U) and eptifibatide (180  $\mu g$  / kg) were administered initially and eptifibatide (2  $\mu$ g / kg / minute) was continued throughout the procedure. A Fluency Plus covered stent (Bard Inc.; Karlsruhe, Germany) was deployed successfully across the fistula. Control angiography of the left VA demonstrated complete closure of the fistula with preservation of flow to the intracranial circulation [Figure 1c], and reversal of the contralateral flow from the right VA [Figure 1d]. Post procedural Q-MRA demonstrated normalization of the antegrade flow through the left VA distal to the fistula at 143 ml / minute, with a combined total of 261 ml / minute within both vertebral arteries, (the normal range of combined vertebral flow was 99 - 281 mg / minute) [Figures le and f].

Postoperatively the patient remained neurologically intact and was started on dual anti-platelet therapy with daily aspirin (325 mg) and clopidogrel (75 mg). Eptifibatide was discontinued the morning after the procedure. On follow-up, the patient's tinnitus had resolved, and angiography at four months demonstrated complete exclusion of the VJF and patency of the covered stent.

### Case 2

A 62-year-old male with a history of stage II laryngeal squamous cell carcinoma was treated with total laryngectomy, bilateral neck dissection, tracheostomy, and adjuvant radiation therapy. The patient suffered tumor recurrence in the pharynx, and was being treated with palliative chemotherapy. He presented with severe, acute bleeding from the mouth and bilateral nares, which required emergent intubation and extensive packing of the nasal and oral cavities. Angiography demonstrated left common carotid artery (CCA) blowout with a pseudoaneurysm at the carotid bifurcation [Figure 2a]. Circumferential ulceration suggestive of CBS was also identified at the bifurcation of the right internal carotid artery (ICA).

Due to surgical scarring, radiation, and tumor recurrence, the surgery carried a high risk of morbidity and mortality. It was elected to endovascularly reconstruct the carotid arteries with covered stents. A Fluency Plus stentgraft was successfully deployed effectively covering the common carotid bifurcation and the proximal aspect of the cervical segment of the left ICA. Control angiography showed complete exclusion of the pseudoaneurysm as well as the external carotid artery [Figure 2b].

A Fluency Plus stent-graft was also deployed across the right carotid bifurcation. During advancement of the Stent, dissection of the proximal CCA was noted. Subsequently, two Precise Nitinol stents (Cordis Corporation; Miami Lakes, FL) were successfully deployed across the iatrogenic dissection. Control angiography demonstrated the near-normal caliber of the right common carotid artery with the three stents in tandem. Systemic heparinization was continued for 24 hours, after which the patient was maintained on dual anti-platelet therapy. Post-procedurally no new neurological deficits were identified. He was ultimately discharged to a nursing home and was lost to follow-up.

### Case 3

A 53-year-old female with a history of stage II squamous cell carcinoma of the larynx was treated with radical laryngectomy with bilateral neck dissection, tracheostomy, and radiation therapy. The patient suffered tumor recurrence in the pharynx, and presented with severe, acute bleeding from the mouth. She was emergently intubated and hemostasis was achieved by packing the nasal and oral cavities. Angiography demonstrated a left CCA blowout with a pseudoaneurysm at the carotid bifurcation. This was treated with endovascular deployment of a Fluency covered stent graft with no immediate complications and was maintained on dual anti-platelet therapy. The patient died six months later from cancer recurrence.

### **REVIEW OF THE LITERATURE**

We conducted a systematic review of the English-speaking medical literature using the PubMed service of the National Library of Medicine / National Institutes of Health and OVID



Figure 1: (a) LeftVA angiogram showing an AVF draining into bilateral internal jugular veins and diffuse fibromuscular dyspastic change; (b) RightVA injection showing retrograde filling of the distal leftVA into the rightVA-jugular vein fistula, and diffuse fibromuscular dysplastic change; (c) after deployment of the stent-graft showing complete occlusion of the AVF with normalization of the antegrade flow within the intracranial portion of the leftVA; (d) RightVA injection showing no cross flow of contrast into the left intracranialVA; (e) 3 D-imaging from a Q-MRA, showing reconstitution of the leftVA with no opacification of the fistula; (f) Q-MRA flow maps indicating 151 ml / minute of antegrade blood flow within the leftVA compared to 744 ml / minute at the baseline



Figure 2: (a) Left CCA angiogram showing a pseudoaneurysm at the carotid bifurcation; (b) exclusion of the pseudoaneurysm after deployment of the covered stent

Medline databases to identify all publications documenting the use of covered stents in the extracranial cerebral circulation. The search included the keywords 'Stents' [Mesh] AND ('Vertebral Artery' [Mesh] OR 'Carotid Artery Injuries' [Mesh] NOT 'Intracranial Arterial Diseases' [Mesh] NOT 'Subclavian artery' [MESH] NOT 'Carotid-Cavernous Sinus Fistula' [Mesh]. Additionally, the reference lists of the relevant articles were checked until no further publications were found. These publications are summarized in Table 1.[1.2,4,5,7,8,11,13,15,16,19,25,27-32,34,35,37,38,41,42,45,49,51,52,54,57,59-63,65,66,68-73,75-77,79,80,82-85,87,89-92,94-98,100,101,103,104,106,109,112-114]

### **DISCUSSION**

### Indications for covered stents

A total of 150 patients, including the present cases, were endovascularly implanted with 164 covered stents for the treatment of extracranial disease of the carotid or vertebral arteries [Table 1]. Publication bias may have resulted in the underestimation of these figures, as failed procedures are occasionally not publicized. The most commonly reported indications included 81 pseudoaneurysms, 27 cases of CBS, and 23 AVFs. Additional reported indications included

Table 1: Extracr	anial neu	rovascular in	nterventions with covered stents: bil	bliography review			
Authors (first)	Year	Age/Sex	Indication	Device or Stent/Graft	Outcome	<b>Complications</b>	Follow-up
Nicholson	1995	59/M	PSA of the left	CCACraggstent	Lesion excluded	None	8 w: patent
Singer	1997	34/F	VJF involving the left VA	Palmaz/Gortex	Lesion excluded	None	17 mo: patent
May	1997	70/M	PSA of the right ICA	Passager endograft	Lesion excluded	Embolic stroke	6 mo: asymptomatic occlusion
Reiter	1998	72/M	PSA of the left ICA	Palmaz/PTFE	Lesion excluded	None	6 mo: patent
Von	1998	67/M	PSA of the left CCA	Palmaz/Saphenous	Lesion excluded	None	2 mo: patent
Nieuwenhove				vein			
Waldman	1998	44/M	Dissection of the left VA	CEG	Lesion excluded	None	1 wk: patent
Marotta	1998	20/M	PSA of the left ICA	Palmaz 154/saphenous	Lesion excluded	None	1 mo: patent
				vein			
Parodi	1999	23/M	PSA of the CCA	Palmaz/Saphenous	Lesion excluded	None	18 mo: asymptomatic occlusion
				Vein			
		37/M	PSA of the ICA	Palmaz/Saphenous	Lesion excluded	None	36 mo: patent
				vein			
		22/M	CJF involving the CCA	CEG	Lesion excluded	None	24 mo: patent
		21/M	CJF involving the CCA	CEG	Lesion excluded	None	6 mo: patent
		53/M	CJF involving the ICA	CEG	Lesion excluded	None	4 mo: patent
		23/M	CJF involving the CCA	CEG	Lesion excluded	None	8 mo: patent
		12/M	PSA of the ICA	Wallgraft	Lesion excluded	None	1 mo: patent
Smith	2000	28/W	PSA of the left ICA	Palmaz/PTFE x 2	Lesion excluded	None	6 mo: patent (PSA filling)
				Dolmo-/Conhonene		Alore A	
IVIALUIT	7000	INI/RC		raima <i>q</i> sapnenous vein	Lesion excluded	NOLIE	o IIIO. pateitt
Simionato	2000	50/M	PSA of the right CCA	Jostent x 2	Lesion excluded	None	12 mo: patent
Macdonald	2001	61/M	CBS of the right CCA	Jostent	Lesion excluded	None	
Kwok	2001	63/M	CBS of the right CCA	Jostent	Vessel rupture		
Buckert	2001	13/F	V.IF involving the right VA	.Instent	l esion excluded	None	15 mo: natent
Gonzalez	2001	57/E	V IF involving the right VA	W/alloraft	l ecion evoluded	None	0 mo: natent
	1002	1//C		vvaligiait Isotoot	Lesion evoluada		
ocavee		1VI/SC	POA OT THE FIGHT ICA	JOSTEILT	Lesion excluded	INONE	o mo: patent
Redekop	2001	20/M	PSA of the ICA	Palmaz/Saphenous vein	Lesion excluded	None	3 mo: patent
		60/F	VVF	Palmaz/Saphenous	Lesion excluded	None	6 mo: patent
				Vein			
		16/M	CJF involving the left ICA	Palmaz/PTFE x 3	Lesion excluded	None	3 mo: patent
Patel	2002	29/M	PSA of the left CCA	Wallgraft	Lesion excluded	None	6 mo: patent
Ellis	2002	43/M	PSA of the left ICA	Wallgraft	Lesion excluded	None	9 mo: patent
Mukherjee	2002	65/M	PSA of the right ICA	Wallgraft	Lesion excluded	None	8 mo: patent
		64/M	PSA of the right CCA/ICA	Wallgraft x 2	Lesion excluded	None	9 mo: patent
Lesley	2002	46/M	CBS of the ICA	Wallgraft	Hemostasis	None	
		41/F	CBS of the ECA	Wallgraft	Hemostasis	None	

Contd....

Table 1: <i>Contd.</i>	:						
Authors (first)	Year	Age/Sex	Indication	Device or Stent/Graft	Outcome	Complications	Follow-up
		75/M	CBS of the ICA	Palmaz/Saphenous vein	Technical failure		
McNeil	2002	18/M	PSA of the left ICA	Wallgraft	Lesion excluded	None	10 mo: 50% stenosis
Duane	2002	31/F	PSA of the left ICA	Wallgraft	Lesion excluded	ICA dissection	6 wk: ICA occlusion
		27/F	CJF involving the right ICA	Palmaz/PTFE	Lesion excluded	None	2 yr: patent
Amar	2002	47/M	CBS of the right CCA	Wallgraft x 2	Hemostasis	None	1
		38/F	VVF involving the right VA	Wallgraft	Lesion excluded	None	6 d: patent
		35/M	PSA of the left ICA	Wallgraft	Lesion excluded	None	1
Duncan	2003	22/M	CJF involving the right ICA	Wallgraft	Lesion excluded	None	6 mo: patent
Tseng	2003	68/M	PSA of the left ICA	Jostent x 2	Lesion excluded	None	9 mo: patent
Ahn	2003	32/M	CJF and PSA of the left ICA	Jostent	Lesions excluded	None	1 wk: patent
Hertz	2003	80/M	PSA of the right CCA	Wallgraft x 2	Lesion excluded	None	
Lupattelli	2003	40/M	PSA of the left ICA	Jostent	Lesion excluded	None	20 mo: patent
du Toit	2003		CJF involving the CCA				1
			CJF involving the CCA				
			CJF involving the CCA				
			CJF involving the ICA				
Koenigsberg	2003	33/M	PSA of the left CCA	Wallgraft	Lesion excluded	None	1 yr: clinically asymptomatic
Sadato	2003	24/F	VVF involving the right VA	Palmaz/PTFE	Lesion excluded	None	5 mo: patent
Surber	2003	42/F	VVF involving the right VA	Wallgraft	Lesion excluded	None	12 mo: patent
Lin	2003	74/M	PSA of the right CCA/ICA	Wallgraft	Lesion excluded	None	18 mo: patent
Kubaska	2003	39/M	PSA of the left ICA	Wallgraft	Lesion excluded	None	2 yr: clinically asymptomatic
		40/M	PSA of the left ICA	Wallgraft	Lesion excluded	None	1 mo: patent
		34/W	PSA of the right ICA	Wallgraft	Lesion excluded	None	14 mo: patent
		67/M	PSA of the left ICA	Wallgraft x 2	Lesion excluded	None	6 mo: patent
Powell	2003	54/M	Vein-graft aneurysm of right CCA	Viabahn	Lesion excluded	None	4 mo: patent
Priestley	2003	45/M	VVF involving the right VA	Hemobahn	Lesion excluded	VA dissection	6 mo: patent
Assadian	2004	43/F	Dissection of the ICA	Hemobahn	Lesion excluded	None	45 mo: patent
		49/F	Dissection of the ICA	Hemobahn	Lesion excluded	None	54 mo: patent
		34/M	Dissection of the ICA	Hemobahn	Lesion excluded	None	6 mo: patent
		78/M	Dissection of the ICA	Hemobahn	Lesion excluded	None	35 mo: patent
		64/M	Dissection of the ICA	Hemobahn	Lesion excluded	None	48 mo: patent
		49/M	Dissection of the ICA	Hemobahn	Lesion excluded	TIA	42 mo: patent
Fusonie	2004	37/M	PSA of the right ICA	Wallgraft	Lesion excluded	None	3 mo: patent
Saket	2004	18/M	PSA of the right ICA	Palmaz/PTFE	Lesion excluded	Type I endoleak	None
		28/M	PSA of the left ICA	Hemobahn	Lesion excluded	None	46 mo: patent
		33/W	VJF involving the right VA	Jostent	Lesion excluded	None	14 mo: patent
							Contd

Table 1: <i>Contd.</i>	:						
Authors (first)	Year	Age/Sex	Indication	Device or Stent/Graft	Outcome	Complications	Follow-up
		46/M	PSA of the right ICA	Jostent	Lesion excluded	None	14 mo: patent
		92/W	PSA of the left CCA	Viabahn	Lesion excluded	None	
Felber	2004	31/M	Dissection of the right ICA	Jostent	Lesion excluded	None	4 yr: patent
		46/M	CBS of the left ICA	Jostent	Hemostasis	TIA	3 mo: patent
		45/M	Dissection of the right VA	Jostent	Lesion excluded	None	5 yr: patent
		66/F	VJF	Jostent	Lesion excluded	None	14 mo: patent
ul Haq	2004	39/M	PSA of the left ICA	Jostent	Lesion excluded	None	6 mo: patent
		12/M	PSA of the left CCA	Jostent	Lesion excluded	None	3 mo: patent
Huttl	2004	24/M	PSA and VVF of the left VA	Jostent	Lesions excluded	None	18 mo: L VA occlusion
Baril	2004	W/67	Infected PSA of the right CCA	Viabahn	Lesion excluded	None	12 mo: patent
Self	2004	32/M	PSA and CJF of the right CCA	Wallgraft	Lesions excluded	None	1
Layton	2004	31/F	PSA of the left ICA		Lesion excluded	None	27 mo: patent
		23/M	PSA of the left ICA		Lesion excluded	None	8 mo: patent
		63/F	In-stent stenosis of the right CCA		Lesion excluded	None	3 yr: patent
Zingler	2004	63/M	VVF invovling the right VA	Jostent	Lesion excluded	None	
Cil	2004	57/M	Stenosis of the left ICA	Palmaz/PTFE		None	6 mo: patent
		47/M	Stenosis of the left ICA	Palmaz/PTFE		None	6 mo: patent
		67/M	Stenosis of the right ICA	Palmaz/PTFE		None	6 mo: patent
Joo	2004	32/M	PSA and CJF of the left ICA	Jostent	Lesions excluded	None	10 mo: patent
McCready	2004	58/M	PSA of the left ICA	Wallgraft x 2	Lesion excluded	TIA	12 mo: asymptomatic occlusion
		,	PSA	Wallgraft	Lesion excluded	TIA	12 mo: patent
			PSA	Wallgraft	Lesion excluded	None	12 mo: patent
		,	PSA	Wallgraft	Lesion excluded	None	ı
Szopinski	2005	37/M	PSA of the right ICA	Jostent	Lesion excluded	None	5 yr: clinically asymptomatic
		64/M	PSA of the right ICA	Jostent	Lesion excluded	None	3 yr: clinically asymptomatic
		56/M	Aneurysm of the left CCA/ICA	Wallgraft	Lesion excluded	None	2 yr: clinically asymptomatic
Mousa	2005	82/W	PSA of the right CCA/ICA	Wallgraft	Lesion excluded	None	6 mo: patent
Dieter	2005	67/M	Perforation of the right ICA	Jostent	Lesion excluded	None	1 mo: patent
Неуе	2005	44/M	PSA of the right ICA	Symbiot	Lesion excluded	None	4 mo: patent
Akiyama	2005	48/M	PSA of the right CCA	Jostent	Lesion excluded	None	6 mo: patent
Witz	2005	16/M	PSA of the left CCA	Jostent	Lesion excluded	None	1 yr: patent
Maras	2006	22/M	PSA of the left ICA	Jostent	Lesion excluded	None	18 mo: patent
Hagspiel	2006	54/W	CBF involving the left CCA	iCAST x 2	Lesion excluded	None	6 wk: clinically asymptomatic
Katsaridis	2006	74/M	PSA of the right VA	Symbiot	Lesion excluded	None	6 mo: patent
Сох	2007	ı	PSA of the VA	icast	Lesion excluded	None	
			PSA of the ICA	Wallgraft	Lesion excluded	None	

Contd....

Table 1: Conta	<u>.</u>						
Authors (first)	Year	Age/Sex	Indication	Device or Stent/Graft	Outcome	Complications	Follow-up
Riesenman	2007	86/F	PSA of the right ECA	Jostent	Lesion excluded	None	2 mo: patent
Briguori	2007	76/M	PSA of the left CCA	Fluency	Lesion excluded	None	3 mo: patent
Lim	2007	26/F	PSA of the left ICA $ imes$ 2	Symbiot	Lesion excluded	ICH	Died: ruptured aortic aneurysm
Chang	2007	35/M	CBS of the CCA/ICA	Wallgraft	Hemostasis	ICA occlusion	Rebled 19 days post-procedure
		43/M	CBS of the CCA	Wallgraft	Hemostasis	None	Rebled two days post-procedure
		52/M	CBS of the ICA	Wallgraft	Hemostasis	ICA thrombosis	6 mo: asymptomatic occlusion
		49/M	CBS of the CCA/ICA	Wallgraft	Hemostasis	Embolic stroke	1 mo: patent
		52/M	CBS of the CCA/ICA	Wallgraft	Hemostasis	Brain abscess	4 mo: septic carotid thrombosis
		65/M	CBS of the CCA/ICA	Wallgraft	Hemostasis	None	5 mo: asymptomatic thrombosis
		44/M	CBS of the CCA	Wallgraft	Hemostasis	None	2 wk: patent
		54/M	CBS of the CCA	Wallgraft	Hemostasis	None	2 wk: patent
Barkhordarian	2007	63/M	PSA and VJF of the right VA	Jostent	Lesions excluded	None	6 mo: patent
Feugier	2007	44/M	Dissection of the right ICA	Advanta V12	Lesion excluded	None	2 yr: patent
Sancak	2008	22/M	PSA and VJF of the left VA	Jostent x 2	Lesions excluded	None	18 mo: in-stent stenosis
Bellosta	2008	59/M	PSA of the left CCA/ICA	Viabahn	Lesion excluded	None	6 mo: patent
Yi	2008	44/M	PSA of the left ICA	Fluency	Lesion excluded	None	15 d: patent
		66/M	PSA of the right ICA	Viabahn	Lesion excluded	None	ı
		15/M	PSA of the left CCA	Fluency	Lesion excluded	None	25 mo: patent
		81/M	PSA of the left CCA	Fluency	Lesion excluded	Embolic stroke	ı
		17/F	PSA of the right ICA	icast	Lesion excluded	None	20 mo: patent
		62/M	PSA of the left CCA	Fluency	Lesion excluded	None	5 d: patent
		24/M	PSA of the left CCA	Fluency	Lesion excluded	None	13 d: patent
Hoppe	2008	61/F	CBS of the right CCA/ICA	Palmaz/PTFE	Hemostasis	None	1 mo: asymptomatic occlusion
		86/F	CBS of the left CCA	Palmaz/PTFE	Hemostasis	CCA dissection	ı
		75/M	CBS of bilateral CCAs	Palmaz/PTFE x 2	Hemostasis	None	Rebled 9 days post-procedure
		67/F	CBS of the left CCA	Fluency	Hemostasis	None	4 mo: patent
		62/F	CBS of the right CCA/ICA	Fluency	Hemostasis	None	6 mo: patent
		33/M	CBS of the right CCA	Wallgraft	Hemostasis	None	Rebleed 24 hrs post-procedure
		87/F	CBS of the left ICA	Wallgraft	Hemostasis	None	I
		63/F	CBS of the left CCA/ICA	Wallgraft	Hemostasis	None	ı
		61/M	CAF involving the right CCA	Fluency	Lesion excluded	None	ı
		64/F	CAF involving the right CCA	Viabahn	Lesion excluded	None	
		52/M	CAF involving the right CCA	Viabahn	Lesion excluded	None	
		68/M	PSA of the left CCA/ICA	Fluency	Lesion excluded	None	
		20/F	PSA of the left ICA	Viabahn	Lesion excluded	None	6 mo: patent
		67/M	PSA of the right ICA	Viabahn	Lesion excluded	None	33 mo: patent

Contd....

Authors (first)	Year	Age/Sex	Indication	Device or Stent/Graft	Outcome	Complications	Follow-up
		47/M	PSA of the right ICA	Viabahn	Lesion excluded	None	18 mo: patent
		63/F	PSA of the left CCA	Fluency	Lesion excluded	None	6 mo: patent
		67/F	PSA of the left CCA	Fluency	Lesion excluded	None	6 mo: patent
		57/M	PSA of the right ICA	Viabahn	Lesion excluded	None	6 mo: patent
		65/M	PSA of the left CCA	Fluency	Lesion excluded	None	6 mo: patent
		65/M	Stenosis of the left CCA/ICA	Fluency	Lumen expanded	None	6 mo: patent
		80/M	Stenosis of the right ICA	Viabahn	Lumen expanded	None	6 mo: patent
Flood	2009	24/F	PSA of the right ICA	Jostent x 2	Lesion excluded	None	1 yr: in-stent restenosis
This study	2011	51/F	VJF involving the left VA	Fluency	Lesion excluded	None	4 mo: patent
		62/M	CBS of the CCA bilaterally	Fluency x 2	Lesion excluded	None	
		53/F	CBS of the of the left CCA/ICA	Fluency	Lesion excluded	None	
CCA = common c CBF = caroticobra	arotid artery; chiocephalic fi	ICA = internal car istula; CBS = carot	rotid artery; ECA = external carotid artery;VA = ve tid blowout syndrome; CAF = carotid-airway fistula	rtebral artery; PSA = pseudoa ; CEG = Corvita endoluminal s	neurysm; CJF = carotid-jugular fis stent-graft; PTFE = polytetrafluorc	tula;VJF = vertebrojugular bethylene; ICH = intracere	fistula;VVF = vertebrovertebral fist bral hemorrhage; SAH = subarachn
hemorrhage. U= d;	ays; wk = wee	ks; mo = months; )	yr = years				

http://www.surgicalneurologyint.com/content/2/1/67

dissections, carotid-airway fistulas, in-stent stenosis, and atherosclerosis [Table 1].

A pseudoaneurysm forms secondary to vessel wall trauma that results in a periarterial hematoma contained in the ingrowth of the fibrotic tissue. As the center of the hematoma dissolves, a potential space for blood flow is created, which under arterial pressure gradually enlarges to form an aneurysmal sac.<sup>[9]</sup> Blood may also dissect through the subintimal or subadventitial space narrowing the true lumen of the vessel.<sup>[22]</sup> Pseudoaneurysms may be caused by blunt or penetrating craniocervical trauma, spontaneous dissection, and as a rare complication of carotid endarterectomy.<sup>[20]</sup> The most common clinical presentations include thromboembolic symptoms<sup>[78]</sup> or a pulsatile cervical mass or bruit on physical examination.<sup>[74]</sup> Treatment is recommended to reduce the risk of stroke and rupture.

Arteriovenous fistulas involving the extracranial carotid and vertebral arteries are rare.<sup>[27,107]</sup> Like pseudoaneurysms, these lesions most commonly occur secondary to blunt or penetrating neck trauma.<sup>[50]</sup> Iatrogenic lesions are caused by an arterial puncture with concomitant damage to an adjacent vein.<sup>[102]</sup> Other causes include systemic diseases such as neurofibromatosis<sup>[98]</sup> and fibromuscular dysplasia,<sup>[39]</sup> which is the presumed etiology in our patient. Treatment is necessary, because shunting through the high-flow AVF may result in cardiac overload.<sup>[44]</sup> Additionally, as seen in our patient, vertebral AVFs may produce a continuous or pulsatile tinnitus also necessitating treatment.<sup>[10]</sup>

Carotid blowout syndrome is a term used to describe a rupture of the extracranial carotid artery or its branches. Patients commonly present with acute transoral or transcervical hemorrhage.<sup>[14]</sup> CBS is a rare, but life-threatening complication of head and neck cancer occurring in 4.3% of these patients.<sup>[67]</sup> The etiological factors related to previous surgery and adjuvant radiation therapy have been implicated.<sup>[67,93]</sup> Our patients with CBS presented with life-threatening bleeding that necessitated packing and acute parent vessel reconstruction with covered stents.

## **Conventional surgical treatment**

Although standard surgical procedures on the extracranial carotid and vertebral arteries are generally straightforward, complex lesions such as those previously discussed pose unique challenges. Historically, surgical options for the treatment of extracranial pseudoaneurysms included vessel ligation, extracranial–intracranial bypass, and direct vessel repair; however, these surgeries are technically challenging. In particular, ICA pseudoaneurysms near the skull base necessitate extensive exposures to achieve proximal and distal control, which may result in significant morbidity and mortality.<sup>[21,33]</sup> Direct repair of VA pseudoaneurysms is also associated with high

morbidity and mortality due to the anatomic depth of the vessel, extensive periarterial plexus, prevalence of collateral blood flow, and risk of vertebrobasilar ischemia.<sup>[12,24,40]</sup>

Surgical treatment of AVFs is similarly difficult. Ideally, the procedure entails interruption of the fistula with arterial and venous reconstruction.<sup>[86,88]</sup> However, the technical challenge and consequent morbidity related to surgical exposure are similar to those of pseudoaneurysm repair.<sup>[29]</sup> Furthermore, the large caliber of the extracranial carotid and vertebral arteries produces large shunts and pressure differences. This results in rich arterial and venous collateral formation and arterialization of the thin-walled veins, which makes surgery even more delicate. If the fistula cannot be fully trapped, ligation of the affected vessel is the only other surgical option.

Surgical management of CBS involves emergent ligation of the affected common or proximal internal carotid artery; however, vessel sacrifice increases the risk of stroke.<sup>[46]</sup> Additionally, these patients are generally high risk candidates for general anesthesia. Furthermore, identification of the source of bleeding can be extremely difficult due to the tumor bulk, coexisting infection or dense scarring secondary to the previous treatment. Consequently, these procedures have been associated with a 60% incidence of neurological complications and 40% overall mortality.<sup>[14,17]</sup>

# Advantages of covered stents in the extracranial vessels

Preserving vessel patency is ideal when treating vascular lesions of the extracranial cerebral circulation. Sacrificing extracranial cerebral vessels increases morbidity and mortality, especially in patients with poor collateral circulation.<sup>[23,56]</sup> Indeed, iatrogenic vertebrobasilar insufficiency has been reported after deliberate sacrifice of one vertebral artery, even after an antecedent balloon test occlusion suggested its safety.<sup>[3]</sup> Additionally, preservation of the complete extracranial cerebral vasculature is desirable in young patients<sup>[49,90]</sup> and patients with systemic vasculatides or connective tissue disorders, where future neurovascular lesions must be anticipated<sup>[62,91,98]</sup>

Because of the risk of surgical complications, endovascular approaches are useful for extracranial cerebral vasculature. Balloon occlusion and coil embolization are commonly used endovascular techniques; however, these procedures sacrifice the parent vessel. Another technique is overlapping bare metal stents, which has been used to trigger hemodynamic changes that accelerate the thrombosis of dissecting pseudoaneurysms; however, this technique has limited utility in cases of an expanding pseudoaneurysm or active bleeding, where an immediate, blood-tight seal is required. Covered stents circumvent these limitations by immediately excluding breaches of the vessel wall while maintaining parent vessel patency.

# History of covered stents in the extracranial vessels

The earliest covered stent used for neurovascular intervention was the Craggstent (Boston Scientific Corp., Natick, MA), later renamed the Passager endograft, which was used in two cases to treat carotid artery pseudoaneurysms.<sup>[71,77]</sup> This device consisted of a self-expanding Nitinol stent covered by a polyester fabric designed and marketed for bypass grafting in the iliac and superficial femoral arteries. The primary disadvantage of this device was that the delivery catheter was too short to allow a percutaneous approach from the groin, thus necessitating direct puncture of the CCA. Early neurovascular interventions were also performed with homemade devices made of Gortex,[97] PTFE<sup>[45,85]</sup> or autologous-vein<sup>[69]</sup> grafts sutured to balloonexpandable Palmaz stents (Johnson and Johnson, New Brunswick, NJ).

The Wallgraft (Boston Scientific, Natick, MA), which consists of a PET (Dacron; E.I. duPont de Nemours and Co., Wilmington, DE) covered self-expanding cobalt super alloy stent, is more widely used. The longitudinal flexibility of this device allows for better conformability to the tortuous arterial walls than the homemade devices;[45] however, the Wallgraft has several important disadvantages. First, PET is highly immunogenic, [26,48,55] which animal studies suggest, increases the rate of vessel thrombosis.<sup>[64]</sup> Second, the Wallgraft delivery system requires a 9-French arterial sheath in the carotid and vertebral arteries, which may increase the risk of pseudoaneurysms or groin hematomas at the femoral puncture site. Finally, the PET covering is initially porous until a clot forms to seal the fabric. In acute bleeding situations, such as CBS, the fabric does not seal rapidly enough to prevent exsanguination.<sup>[99]</sup>

Newer self-expanding devices include the Fluency and Viabahn, which were FDA approved for the treatment of tracheobronchial strictures in 2003 and 2005, respectively. Both are composed of a Nitinol stent covered with PTFE. These devices are more flexible, conform more easily to the vessel walls, and the PTFE covering is less thrombogenic. In recent times, these devices have become available in long delivery sheaths necessary for placement in the extracranial cerebral circulation; however, large delivery sheaths are still required. Other self-expanding devices have been used including the Symbiot,<sup>[52,62]</sup> which is only available in Europe, and the Corvita Endoluminal Stent-Graft,<sup>[109]</sup> which did not come into the market. The primary advantage of self-expanding stents is that they re-expand after external compression. Therefore, self-expanding stents are preferred for the carotid artery<sup>[81]</sup> and at the carotid bifurcation, to accommodate the difference in diameters between the common and internal carotid arteries.[11] In all our cases, four Fluency stents were used, which were all self-

expanding and configured appropriately to match the size of the CCA, ICA, and VA, with immediate angiographic reconstruction of the parent vessel and isolation of the pseudoaneurysm / fistula connection.

Commercially available balloon-expandable covered stents are also available [Table 2]. The most common of these devices is the Jostent Coronary Stent Graft (Abbott, Redwood City, CA), which was FDA approved in 2001. This device consists of a PTFE graft sandwiched between two stainless steel stents. Also available is the iCAST (Atrium Medical Corporation, Hudson, NH), a PTFE-covered, single stainless steel stent, which was FDA approved in 2005, for the treatment of tracheobronchial strictures. An advantage of a balloon-expandable deployment system in treating AVFs is the ability to over-dilate the vessel.<sup>[90]</sup> This firmly fixes the stent, thus avoiding an endoleak between the graft and vessel wall. However, the several drawbacks to these devices are that they are expensive, lack flexibility, are susceptible to mechanical distortion, and require high deployment pressure.<sup>[31]</sup> The latter is particularly important when treating fragile vessels.<sup>[45]</sup>

### **Technical success**

Table 3 summarizes the outcomes of previously reported cases. In our literature review, three technical failures were reported,<sup>[15,59,61,62]</sup> resulting in a technical success rate of 98.2%. Kwok *et al.*,<sup>[52]</sup> reported carotid artery rupture during deployment of a balloon-expandable covered stent for the treatment of CBS. The authors postulated that the cause of the rupture was due to the high pressure required to inflate the stent in an artery already torn by normal blood pressure. In another patient treated for CBS, Lesley *et al.*,<sup>[61]</sup> reported a vein-covered Palmaz stent that failed to deploy. Finally, surgeons treating a patient with Ehlers-Danlos Syndrome type IV were unable to

treat an ICA aneurysm just below the skull base, because the Symbiot covered stent would not negotiate the vessel tortuosity.<sup>[62]</sup>

### **Complications associated with covered stents**

Immediate complications occurred in 15 of 164 procedures (9.1%). Embolic complications during covered stent placement are due to dissection or rupture and embolization of the atheromatous plaque. Two patients (1.2%) described by May *et al.*,<sup>[71]</sup> and Chang *et al.*,<sup>[15]</sup> suffered embolic strokes, the former during treatment of a pseudoaneurysm post carotid endarterectomy, and the latter for CBS. Six additional patients experienced post-procedural transient ischemic attacks.<sup>[5,31]</sup>

Dissections were encountered in three cases (1.8%).<sup>[28,45,83]</sup> Duane *et al.*,<sup>[8]</sup> reported an ICA dissection during covered stent placement for the treatment of a traumatic pseudoaneurysm. The patient was maintained on anticoagulation therapy, because endovascular treatment was delayed in order to allow healing of the operative site; however, at follow-up the stent was thrombosed. Priestley *et al.*,<sup>[83]</sup> reported a VA dissection during treatment for an AVF that resolved spontaneously by six months. Hoppe *et al.*,<sup>[45]</sup> reported a dissection of the CCA in a patient being treated for CBS. The dissection was treated with two bare self-expanding Nitinol stents and a follow-up angiography demonstrated normal luminal integrity.

Additional immediate complications were reported by Chang *et al.*,<sup>[15]</sup> who described two cases (1.8%) of acute, asymptomatic thrombosis of the CCA after covered stent deployment for the treatment of CBS. In one case the thrombosis was successfully lysed by intravenous glycoprotein IIb / IIIa inhibitor infusion. Also, Lim *et al.*,<sup>[62]</sup> reported a patient with Ehlers-Danlos Syndrome type IV, treated for a carotid dissecting pseudoaneurysm, who died five hours after the procedure from a previously

Table 2: Balloon-expandable covered stents used in extracranial neurovasculature

Device	Manufacturer	Construction	Comments
Jostent coronary stent graft	Abbott (Redwood city, CA)	PTFE graft sandwiched between two stainless steel stents	
iCAST	Atrium Medical Corporation (Hudson, NH)	PTFE covered single stainless steel stent	
Symbiot	Boston Scientific (Natick, MA)	Nitinol stent covered with PTFE	Only available in europe
Corvita endoluminal stent-graft	Corvita corp. (Miami, FL)	Braided, metallic mesh tube covered with layers of polycarbonate urethane fibers	Did not come to market

PTFE = polytetrafluoroethylene

Table 3: S	Self-exp	anding	covered	stents	used in	extracranial	neurovasculatu	ſe

Device	Manufacturer	Construction	Comments
Craggstent	Boston Scientific Corp. (Natick, MA)	Nitinol stent covered with polyester fabric	Also known as Passager endograft
Wallgraft	Boston Scientific Corp. (Natick, MA)	Cobalt super alloy stent covered with PET	
Fluency	Bard (Tempe, AZ)	Nitinol stent covered with PTFE	
Viabahn / Hemobahn	Gore and Associates (Flagstaff, AZ)	Nitinol stent covered with PTFE	

PET = polyethylene terephthalate; PTFE = polytetrafluoroethylene

undiagnosed ruptured abdominal aortic aneurysm. Such remote vascular complications have been reported during neurointerventional procedures in these patients;<sup>[47,105]</sup> however, the authors did not encounter any difficulties traversing the abdominal aorta. Finally, Kwok *et al.*,<sup>[59]</sup> reported rupture of the target vessel during covered stent deployment as discussed a little earlier in the text.

Seven of the 25 patients (28%) treated for CBS suffered re-hemorrhage after initial hemostasis was achieved with covered stent implantation.<sup>[15,45]</sup> Four patients suffered re-hemorrhage secondary to disease progression, [40,54] between 19 days and two months after the initial treatment. One patient suffered a fatal re-bleed two days after treatment, possibly from inadequate covered stent placement due to the patient's critical clinical status. Another patient suffered a re-bleed nine days after covered stent placement, due to a residual flow around the device. Attempted balloon angioplasty expansion of the stent caused it to rupture, resulting in massive extravasation. The re-bleed in one patient was attributed to disseminated intravascular coagulation, as there were no complications associated with the placement of a covered stent. Other reported delayed complications included one patient who developed multiple brain abscesses secondary to septic thrombosis of the carotid artery<sup>[40]</sup> and one patient treated with a PTFE covered Palmaz stent, who developed a small type-1 endoleak, three days after the procedure.<sup>[91]</sup>

Subacute thrombosis and intimal hyperplasia leading to in-stent stenosis or vessel occlusion are the primary complications associated with covered stents. The graft material may delay endothelialization<sup>[26]</sup> resulting in thrombotic occlusion of the stented vessel.<sup>[6]</sup> Additionally, traumatized vessels are hypercoagulable. Placement of a covered stent further retards the flow, which may compound the risk of occlusion.<sup>[18]</sup> Other factors contributing to stent occlusion include graft material, [26,48,55] small vessel size, dissection, and underdilation of the stent.<sup>[84]</sup> In contrast, the synthetic layers of the covered stents theoretically act as mechanical barriers that allow only minimal intimal hyperplasia. However, end-stent stenosis is more common with covered stents compared to conventional stents,<sup>[36]</sup> and it has been suggested that stenosis primarily occurs adjacent to a bend or kink.<sup>[111]</sup> There is no evidence to suggest an appropriate time to stop dual anti-platelet therapy. There is no consensus in the reviewed published literature regarding the type and duration of anti-platelets and / or anti-coagulation therapy. In some of the published data, patients were treated with aspirin alone; other reports indicate treatment with aspirin and plavix, others with aspirin and warfarin. The duration of anti-coagulation and / or anti-platelets vary from one month to lifetime treatment. Keeping in mind the large area of synthetic graft material exposure to the circulation, and based

on the best evidence from conventional carotid artery stenting literature for atherosclerotic carotid artery disease, all our patients were maintained on dual antiplatelet therapy for six months, and thereafter continued on aspirin alone.

The long-term patency of covered stents in extracranial cerebral circulation is unknown. Nine of the 109 patients who underwent angiographic follow-up developed total occlusion of the stented vessel, [15,28,45,49,71,72,79] which gave an overall occlusion rate of 8.3%. These cases included four ICA pseudoaneurysms, one VA pseudoaneurysm, and four patients with CBS. Occlusion was asymptomatic in all nine patients. Follow-up in the patients with pseudoaneurysms ranged from two to twenty-three months. Duane et al., [28] cited persistent narrowing at the end of the stent due to an intimal flap as the possible cause of the occlusion. Huttl et al., [49] described total occlusion of a Jostent in the VA at two months, which was attributed to mechanical distortion caused by external mechanical compression. Four cases of subacute carotid thrombosis were reported in patients treated for CBS;<sup>[15,45]</sup> nevertheless, the use of covered stents for immediate hemostatic control in CBS is a reasonable alternative to surgical ligation or permanent balloon occlusion.

In-stent stenosis due to intimal hyperplasia was described in an additional three cases of traumatic ICA pseudoaneurysms,<sup>[34,73,79]</sup> as also one case of a VA pseudoaneurysm with multiple AVFs.<sup>[92]</sup> McNeil *et al.*,<sup>[73]</sup> and Flood *et al.*,<sup>[34]</sup> each reported 50% ICA in-stent stenosis following placement of a Wallgraft and Jostent at 10 months and one year, respectively. Parodi *et al.*,<sup>[79]</sup> reported 90% ICA in-stent stenosis following placement of a vein-covered Palmaz stent, which progressed to complete occlusion 39 months after initial covered stent placement. Sancak *et al.*,<sup>[92]</sup> reported 50% VA re-stenosis at 18 months successfully treated by balloon angioplasty.

### Additional neurovascular applications

With newer generations of covered stents, intracranial applications might be expanded. Wang *et al.*,<sup>[110]</sup> recently reported 10 patients with direct carotid cavernous fistulas treated with covered stent implantation. Technical failure occurred in one patient due to the rigidity of the covered stent and tortuosity of the ICA. A second patient had recurrence of symptoms the morning after the procedure necessitating ipsilateral ICA occlusion with detachable coils. Of the remaining eight patients, follow-up angiography ranging from five to forty-eight months showed complete exclusion of all direct carotid cavernous fistulas and stent patency without in-stent stenosis.

### CONCLUSION

Covered stents are useful for extracranial neuroendovascular interventions in selected patients,

for the treatment of a variety of lesions, especially pseudoaneurysms, AVFs, and CBS. However, larger studies are required to determine the true incidence of periprocedural complications. The three cases described in this article, and a review of the present literature, suggest that embolic events and dissections are the most frequent immediate complications. Studies evaluating the long-term safety, stent patency, and permanency of hemostasis are also needed. The widespread use of covered stents requires the development of more flexible devices with longer delivery systems, specifically designed for neuroendovascular intervention.

### REFERENCES

- Ahn JY, Chung YS, Lee BH, Choi SW, Kim OJ. Stent-graft placement in a traumatic internal carotid-internal jugular fistula and pseudoaneurysm. J Clin Neurosci 2004;11:636-9.
- Akiyama Y, Nakahara I, Tanaka M, Iwamuro Y, Hayashi J, Harada K, et al.. Urgent endovascular stent-graft placement for a ruptured traumatic pseudoaneurysm of the extracranial carotid artery. J Trauma 2005;58:624-7.
- Amar AP, Levy ML, Giannotta SL. latrogenic vertebrobasilar insufficiency after surgery of the subclavian or brachial artery: Review of three cases. Neurosurgery 1998;43:1450-7.
- Amar AP, Teitelbaum GP, Giannotta SL, Larsen DW. Covered stent-graft repair of the brachiocephalic arteries: technical note. Neurosurgery 2002;51:247-52.
- Assadian A, Senekowitsch C, Rotter R, Zolss C, Strassegger J, Hagmuller GW. Long-term results of covered stent repair of internal carotid artery dissections. J Vasc Surg 2004;40:484-7.
- Baldus S, Koster R, Reimers J, Hamm CW. Membrane-covered stents for the treatment of aortocoronary vein graft disease. Catheter Cardiovasc Interv 2000;50:83-8.
- Baril DT, Ellozy SH, Carroccio A, Patel AB, Lookstein RA, Marin ML. Endovascular repair of an infected carotid artery pseudoaneurysm. J Vasc Surg 2004;40:1024-7.
- Barkhordarian S. Stent graft repair of traumatic vertebral pseudoaneurysm with arteriovenous fistula. Vasc Endovascular Surg 2007;41:153-7.
- Beale PJ. Late development of a false aneurysm of the common carotid artery. Br J Surg 1971;58:76-8
- Beaujeux RL, Reizine DC, Casasco A, Aymard A, Rufenacht D, Khayata MH, et al. Endovascular treatment of vertebral arteriovenous fistula. Radiology 1992;183:361-7.
- Bellosta R, Sesana M, Baglini R, Luzzani L, Talarico M, Sarcina A. Endovascular treatment of a symptomatic carotid artery aneurysm with a stent graft. Vasc Endovascular Surg 2008;42:276-8.
- Blickenstaff KL, Weaver FA, Yellin AE, Stain SC, Finck E. Trends in the management of traumatic vertebral artery injuries. Am J Surg 1989;158:101-5.
- Briguori C, Selvetella L, Baldassarre MP. Endovascular repair of a carotid pseudoaneurysm with Fluency Plus stent graft implantation. J Invasive Cardiol 2007;19:E254-7.
- Chaloupka JC, Putman CM, Citardi MJ, Ross DA, Sasaki CT. Endovascular therapy for the carotid blowout syndrome in head and neck surgical patients: Diagnostic and managerial considerations. AJNR Am J Neuroradiol 1996;17:843-52.
- Chang FC, Lirng JF, Luo CB, Guo WY, Teng MM, Tai SK, et al.. Carotid blowout syndrome in patients with head-and-neck cancers: Reconstructive management by self-expandable stent-grafts. AJNR Am J Neuroradiol 2007;28:181-8.
- Cil BE, Akpinar E, Peynircioglu B, Cekirge S. Utility of covered stents for extracranial internal carotid artery stenosis. AJNR Am J Neuroradiol 2004;25:1168-71.
- Citardi MJ, Chaloupka JC, Son YH, Ariyan S, Sasaki CT. Management of carotid artery rupture by monitored endovascular therapeutic occlusion (1988-1994). Laryngoscope 1995;105:1086-92.
- Cothren CC, Moore EE, Ray CE Jr, Ciesla DJ, Johnson JL, Moore JB, et al.. Carotid artery stents for blunt cerebrovascular injury:risks exceed benefits.

Arch Surg 2005;140:480-5.

- Cox MW, Whittaker DR, Martinez C, Fox CJ, Feuerstein IM, Gillespie DL. Traumatic pseudoaneurysms of the head and neck: Early endovascular intervention. J Vasc Surg 2007;46:1227-33.
- De Filippo CM, Modugno P, Nasso G, Canosa C, Spatuzza P, Testa N, et al.. Pseudoaneurysm after patch-free carotid bifurcation endarterectomy: A case report.Vasc Endovascular Surg 2007;41:448-51.
- de los Reyes RA, Moser FG, Sachs DP, Boehm FH. Direct repair of an extracranial vertebral artery pseudoaneurysm: case report and review of the literature. Neurosurgery 1990;26:528-33.
- DeFatta RJ, Verret DJ, Bauer P. Extracranial internal carotid artery pseudoaneurysm. Int J Pediatr Otorhinolaryngol 2005;69:1135-9.
- Demetriades D, Theodorou D, Asensio J, Golshani S, Belzberg H, Yellin A, et al.. Management options in vertebral artery injuries. Br J Surg 1996;83:83-6.
- 24. Detwiler K, Godersky JC, Gentry L. Pseudoaneurysm of the extracranial vertebral artery. Case report. J Neurosurg 1987;67:935-9.
- Dieter RS, Ikram S, Satler LF, Babrowicz JC, Reddy B, Laird JR. Perforation complicating carotid artery stenting: the use of a covered stent. Catheter Cardiovasc Interv 2006;67:972-5.
- Dolmatch BL, Tio FO, Li XD, Dong YH.Patency and tissue response related to two types of polytetrafluoroethylene-covered stents in the dog. J Vasc Interv Radiol 1996;7:641-9.
- du Toit DF, Leith JG, Strauss DC, Blaszczyk M, Odendaal Jde V, Warren BL. Endovascular management of traumatic cervicothoracic arteriovenous fistula. Br J Surg 2003;90:1516-1521
- Duane TM, Parker F, Stokes GK, Parent FN, Britt LD. Endovascular carotid stenting after trauma. J Trauma 2002;52:149-53.
- Duncan IC, Fourie PA. Percutaneous management of concomitant posttraumatic high vertebrovertebral and caroticojugular fistulas using balloons, coils, and a covered stent. J Endovasc Ther 2003;10:882-6.
- Ellis PK, Kennedy PT, Barros D'Sa AA. Successful exclusion of a high internal carotid pseudoaneurysm using the Wallgraft endoprosthesis. Cardiovasc Intervent Radiol 2002;25:68-9.
- Felber S, Henkes H, Weber W, Miloslavski E, Brew S, Kuhne D. Treatment of extracranial and intracranial aneurysms and arteriovenous fistulae using stent grafts. Neurosurgery 2004;55:631-8.
- Feugier P, Vulliez A, Bina N, Floccard B, Allaouchiche B. Urgent endovascular covered-stent treatment of internal carotid artery injury caused by a gunshot. Eur J Vasc Endovasc Surg 2007;34:663-5.
- Fleischer AS, Guthkelch AN. Management of high cervical-intracranial internal carotid artery traumatic aneurysms. J Trauma 1987;27:330-2.
- Flood J, Bussiere M, Teefy P, Gulka I, Lownie S, Pelz D. In-stent stenosis following covered stent-graft placement. Can J Neurol Sci 2009;36:248-51.
- Fusonie GE, Edwards JD, Reed AB. Covered stent exclusion of blunt traumatic carotid artery pseudoaneurysm: Case report and review of the literature. Ann Vasc Surg 2004; 18:376-9.
- Gercken U, Lansky AJ, Buellesfeld L, Desai K, Badereldin M, Mueller R, et al.. Results of the Jostent coronary stent graft implantation in various clinical settings: Procedural and follow-up results. Catheter Cardiovasc Interv 2002;56:353-60.
- Gonzalez A, Mayol A, Gil-Peralta A, Gonzalez-Marcos JR. Endovascular stent-graft treatment of an iatrogenic vertebral arteriovenous fistula. Neuroradiology 2001;43:784-6.
- Hagspiel KD, Komorowski DJ, Shih MC, Peeler BB, Jensen ME. Treatment of carotid arteriovenous fistula with balloon-expandable tracheobronchial covered stent. J Vasc Interv Radiol 2006;17:585-6.
- HalbachVV, Higashida RT, Hieshima GB.Treatment of vertebral arteriovenous fistulas. AJR Am J Roentgenol 1988;150:405-12.
- Hanakita J, Suwa H, Nishihara K, Iihara K, Sakaida H. Giant pseudoaneurysm of the extracranial vertebral artery successfully treated using intraoperative balloon catheters. Neurosurgery 1991;28:738-41.
- Hertz JA, Minion DJ, Quick RC, Moore EM, Schwartz TH, Endean ED. Endovascular exclusion of a postendarterectomy carotid pseudoaneurysm. Ann Vasc Surg 2003;17:558-61.
- Heye S, Maleux G, Vandenberghe R, Wilms G. Symptomatic internal carotid artery dissecting pseudoaneurysm: Endovascular treatment by stent-graft. Cardiovasc Intervent Radiol 2005;28:499-501.
- 43. Hilfiker PR, Razavi MK, Kee ST, Sze DY, Semba CP, Dake MD. Stent-graft therapy for subclavian artery aneurysms and fistulas: Single-center mid-term results.

JVasc Interv Radiol 2000;11:578-84.

- Holman E. Abnormal arteriovenous communications. Great variability of effects with particular reference to delayed development of cardiac failure. Circulation 1965;32:1001-9.
- Hoppe H, Barnwell SL, Nesbit GM, Petersen BD. Stent-grafts in the treatment of emergent or urgent carotid artery disease: review of 25 cases. JVasc Interv Radiol 2008;19:31-41.
- Hoppe H, Wang SL, Petersen BD. Intravascular US-guided direct intrahepatic portocaval shunt with an expanded polytetrafluoroethylene-covered stentgraft. Radiology 2008;246:306-14.
- Horowitz MB, Purdy PD, Valentine RJ, Morrill K. Remote vascular catastrophes after neurovascular interventional therapy for type 4 Ehlers-Danlos Syndrome. AJNR Am J Neuroradiol 2000;21:974-6.
- Hussain FM, Kopchok G, Heilbron M, Daskalakis T, Donayre C, White RA. Wallgraft endoprosthesis: Initial canine evaluation. Am Surg 1998;64:1002-6.
- Huttl K, Sebestyen M, Entz L, Molnar AA, Nemes B, Berczi V. Covered stent placement in a traumatically injured vertebral artery. J Vasc Interv Radiol 2004I15:201-2.
- Jayaraman MV, Do HM, Marks MP. Treatment of traumatic cervical arteriovenous fistulas with N-butyl-2-cyanoacrylate.AJNR Am J Neuroradiol 2007;28:352-4.
- Joo JY, Ahn JY, Chung YS, Chung SS, Kim SH, Yoon PH, et al.. Therapeutic endovascular treatments for traumatic carotid artery injuries. J Trauma 2005;58:1159-66.
- Katsaridis V, Papagiannaki C, Violaris C. Treatment of an iatrogenic vertebral artery laceration with the Symbiot self expandable covered stent. Clin Neurol Neurosurg 2007;109:512-5.
- Kessel D, Robertson I, Scott J, Phipp L. Re: successful exclusion of subclavian aneurysm with covered nitinol stents. Cardiovasc Intervent Radiol 1999;22:86-7.
- Koenigsberg RA, Urrutia V, McCormick D, Alani F, Ryu D, Nair B, Thomas C. Endovascular treatment of a left carotid artery 'bowtie' pseudoaneurysm with a covered Wallgraft stent. J Neuroimaging 2003;13:362-6.
- Krajcer Z, Sioco G, Reynolds T. Comparison of Wallgraft and Wallstent for treatment of complex iliac artery stenosis and occlusion. Preliminary results of a prospective randomized study. Tex Heart Inst J 1997;24:193-9.
- Kropman RH, de Vries JP, Segers MJ. Surgical repair of a gunshot injury to the left carotid artery: Case report and review of literature. Vasc Endovascular Surg 2008;42:180-3.
- Kubaska SM 3<sup>rd</sup>, Greenberg RK, Clair D, Barber G, Srivastava SD, Green RM, et al. Internal carotid artery pseudoaneurysms: treatment with the Wallgraft endoprosthesis. J Endovasc Ther 2003;10:182-9.
- Kudelko PE 2<sup>nd</sup>, Alfaro-Franco C, Diethrich EB, Krajcer Z, Successful endoluminal repair of a popliteal artery aneurysm using the Wallgraft endoprosthesis. J Endovasc Surg 1998;5:373-7.
- Kwok PC, Cheung JY, Tang KW, Wong WK. Re: Endovascular treatment of acute carotid blow-out syndrome. J Vasc Interv Radiol 2001;12:895-6.
- Layton KF, Kim YW, Hise JH. Use of covered stent grafts in the extracranial carotid artery: Report of three patients with follow-up between 8 and 42 months.AJNR Am J Neuroradiol 2004;25:1760-3.
- Lesley WS, Chaloupka JC, Weigele JB, Mangla S, Dogar MA. Preliminary experience with endovascular reconstruction for the management of carotid blowout syndrome. AJNR Am J Neuroradiol 2003;24:975-81.
- Lim SP, Duddy MJ. Endovascular treatment of a carotid dissecting pseudoaneurysm in a patient with Ehlers-Danlos syndrome type IV with fatal outcome. Cardiovasc Intervent Radiol 2008;31:201-4.
- Lin PH, Bush RL, Lumsden AB. Successful stent-graft exclusion of a bovine patch-related carotid artery pseudoaneurysm. J Vasc Surg 2003;38:396.
- Link J, Feyerabend B, Grabener M, Linstedt U, Brossmann J, Thomsen H, et al.. Dacron-covered stent-grafts for the percutaneous treatment of carotid aneurysms: Effectiveness and biocompatibility--experimental study in swine. Radiology 1996;200:397-4010
- Lupattelli T, Garaci FG, Hopkins CE, Simonetti G. Covered stent deployment and follow-up of a case of internal carotid artery pseudoaneurysm. Cerebrovasc Dis 2003;16:98-101.
- Macdonald S, Gan J, McKay AJ, Edwards RD. Endovascular treatment of acute carotid blow-out syndrome. J Vasc Interv Radiol 2000;11:1184-8.
- 67. Maran AG, Amin M, Wilson JA. Radical neck dissection: A 19-year experience. J Laryngol Otol 1989;103:760-4.

- Maras D, Lioupis C, Magoufis G, Tsamopoulos N, Moulakakis K, Andrikopoulos V. Covered stent-graft treatment of traumatic internal carotid artery pseudoaneurysms: A review. Cardiovasc Intervent Radiol 2006;29:958-68.
- Marotta TR, Buller C, Taylor D, Morris C, Zwimpfer T. Autologous vein-covered stent repair of a cervical internal carotid artery pseudoaneurysm: Technical case report. Neurosurgery 1998;42:408-12.
- Martin JB, Bednarkiewicz M, Christenson JT, Rufenacht DA. Endovascular repair using vein-covered stents in the carotid artery bifurcation. Cardiovasc Surg 2002;8:499-502.
- May J, White GH, Waugh R, Brennan J. Endoluminal repair of internal carotid artery aneurysm: A feasible but hazardous procedure. J Vasc Surg 1997;26:1055-60.
- McCready RA, Divelbiss JL, Bryant MA, Denardo AJ, Scott JA. Endoluminal repair of carotid artery pseudoaneurysms: A word of caution. J Vasc Surg 2004;40:1020-3.
- McNeil JD, Chiou AC, Gunlock MG, Grayson DE, Soares G, Hagino RT. Successful endovascular therapy of a penetrating zone III internal carotid injury. JVasc Surg 2002;36:187-90.
- 74. Mokri B, Piepgras DG, Sundt TM Jr, Pearson BW. Extracranial internal carotid artery aneurysms. Mayo Clin Proc 1982;57:310-21.
- Mousa A, Bernheim J, Lyon R, Dayal R, Hollenbeck S, Henderson P, et al.. Postcarotid endarterectomy pseudoaneurysm treated with combined stent graft and coil embolization--a case report. Vasc Endovascular Surg 2005;39:191-4.
- Mukherjee D, Roffi M, Yadav JS. Endovascular treatment of carotid artery aneurysms with stent grafts. J Invasive Cardiol 2002;14:269-72.
- Nicholson A, Cook AM, Dyet JF, Galloway JM. Case report: Treatment of a carotid artery pseudoaneurism with a polyester covered nitinol stent. Clin Radiol 1995;50:872-3.
- Oruckaptan HH, Ozcan OE. Giant extracranial internal carotid artery aneurysm: A rare presentation with an oropharyngeal mass. Otolaryngol Head Neck Surg 2001;125:571-3.
- Parodi JC, Schonholz C, Ferreira LM, Bergan J. Endovascular stent-graft treatment of traumatic arterial lesions. Ann Vasc Surg 1999;13:121-9.
- Patel JV, Rossbach MM, Cleveland TJ, Gaines PA, Beard JD. Endovascular stent-graft repair of traumatic carotid artery pseudoaneurysm. Clin Radiol 2002;57:308-11.
- Phatouros CC, Higashida RT, Malek AM, Meyers PM, Lempert TE, Dowd CF, et al.. Carotid artery stent placement for atherosclerotic disease: Rationale, technique, and current status. Radiology 2002;217:26-41.
- Powell RJ, Rzucidlo EM, Schermerhorn ML. Stent-graft treatment of a large internal carotid artery vein graft aneurysm. JVasc Surg 37:1310-3.
- Priestley R, Bray P, Bray A, Hunter J. latrogenic vertebral arteriovenous fistula treated with a hemobahn stent-graft. J Endovasc Ther 2003;10:657-63.
- Redekop G, Marotta T, Weill A. Treatment of traumatic aneurysms and arteriovenous fistulas of the skull base by using endovascular stents. J Neurosurg 2001;95:412-9.
- Reiter BP, Marin ML, Teodorescu VJ, Mitty HA. Endoluminal repair of an internal carotid artery pseudoaneurysm. J Vasc Interv Radiol 1998;9:245-8.
- Rich NM, Baugh JH, Hughes CW. Popliteal artery injuries in Vietnam. Am J Surg 1969;118:531-4.
- Riesenman PJ, Mendes RR, Mauro MA, Farber MA. Endovascular exclusion of an external carotid artery pseudoaneurysm using a covered stent. Cardiovasc Intervent Radiol 2007;30:1025-8.
- Robbs JV, Carrim AA, Kadwa AM, Mars M. Traumatic arteriovenous fistula: experience with 202 patients. Br J Surg 1994;81:1296-9.
- Ruckert RI, Rutsch W, Filimonow S, Lehmann R. Successful stent-graft repair of a vertebrojugular arteriovenous fistula. J Endovasc Ther 2001;8:495-500.
- Sadato A, Satow T, Ishii A, Takayama M, Hashimoto N. Large vertebral arteriovenous fistula treated with stent-grafts--case report. Neurol Med Chir (Tokyo) 2003;43:250-4.
- Saket RR, Razavi MK, Sze DY, Frisoli JK, Kee ST, Dake MD. Stent-graft treatment of extracranial carotid and vertebral arterial lesions. J Vasc Interv Radiol 2004;15:1151-6.
- Sancak T, Bilgic S, Ustuner E. Endovascular stent-graft treatment of a traumatic vertebral artery pseudoaneurysm and vertebrojugular fistula. Korean J Radiol 2008;9 Suppl:S68-72.
- Sanders EM, Davis KR, Whelan CS, Deckers PJ. Threatened carotid artery rupture: A complication of radical neck surgery. J Surg Oncol 1986;33:190-3.

- Scavee V, De Wispelaere JF, Mormont E, Coulier B, Trigaux JP, Schoevaerdts JC. Pseudoaneurysm of the internal carotid artery: Treatment with a covered stent. Cardiovasc Intervent Radiol 2001;24:283-5.
- Self ML, Mangram A, Jefferson H, Slonim S, Dunn E, Kollmeyer K. Percutaneous stent-graft repair of a traumatic common carotid-internal jugular fistula and pseudoaneurysm in a patient with cervical spine fractures. J Trauma 2004;57:1331-4.
- Simionato F, Righi C, Scotti G. Post-traumatic dissecting aneurysm of extracranial internal carotid artery: Endovascular treatment with stenting. Neuroradiology 1999;41:543-7.
- Singer RJ, Dake MD, Norbash A, Abe T, Marcellus ML, Marks MP. Covered stent placement for neurovascular disease. AJNR Am J Neuroradiol 1997;18:507-9.
- Smith BL, Munschauer CE, Diamond N, Rivera F. Ruptured internal carotid aneurysm resulting from neurofibromatosis: Treatment with intraluminal stent graft. J Vasc Surg 2000;32:824-8.
- Smith TP, Alexander MJ, Enterline DS. Delayed stenosis following placement of a polyethylene terephthalate endograft in the cervical carotid artery. Report of three cases. J Neurosurg 2003;98:421-5.
- Surber R, Werner GS, Cohnert TU, Wahlers T, Figulla HR. Recurrent vertebral arteriovenous fistula after surgical repair: Treatment with a self-expanding stent-graft. J Endovasc Ther 2003;10:49-53.
- 101. Szopinski P, Ciostek P, Kielar M, Myrcha P, Pleban E, Noszczyk W.A series of 15 patients with extracranial carotid artery aneurysms: Surgical and endovascular treatment. Eur J Vasc Endovasc Surg 2005;29:256-61.
- 102. Thalhammer C,Kirchherr AS, Uhlich F,Waigand J, Gross CM. Postcatheterization pseudoaneurysms and arteriovenous fistulas: Repair with percutaneous implantation of endovascular covered stents. Radiology 2000;214:127-31
- 103. Tseng A, Ramaiah V, Rodriguez-Lopez JA, Perkowshi PE, Del Santo PB, Gowda RG, et al. Emergent endovascular treatment of a spontaneous internal carotid artery dissection with pseudoaneurysm. J Endovasc Ther 2003;10:643-6.
- 104. ul Haq T,Yaqoob J, Munir K, Usman MU. Endovascular-covered stent treatment

### http://www.surgicalneurologyint.com/content/2/1/67

of posttraumatic cervical carotid artery pseudoaneurysms.Australas Radiol 2004;48:220-3.

- 105. Usinskiene J, Mazighi M, Bisdorff A, Houdart E. Fatal peritoneal bleeding following embolization of a carotid-cavernous fistula in Ehlers-Danlos syndrome type IV. Cardiovasc Intervent Radiol 2006;29:1104-6.
- 106. Van Nieuwenhove Y, Van den Brande P, van Tussenbroek F, Debing E, von Kemp K. latrogenic carotid artery pseudoaneurysm treated by an autologous veincovered stent. Eur J Vasc Endovasc Surg 1998;16:262-5.
- 107. Vinchon M, Laurian C, George B, D'Arrigo G, Reizine D, Aymard A, et al.. Vertebral arteriovenous fistulas: A study of 49 cases and review of the literature. Cardiovasc Surg 1994;2:359-69.
- Waigand J, Uhlich F, Gross CM, Thalhammer C, Dietz R. Percutaneous treatment of pseudoaneurysms and arteriovenous fistulas after invasive vascular procedures. Catheter Cardiovasc Interv 1999;47:157-64.
- Waldman DL, Barquist E, Poynton FG, NumaguchiY. Stent graft of a traumatic vertebral artery injury: Case report. J Trauma 1998;44:1094-7.
- 110. Wang C, Xie X, You C, Zhang C, Cheng M, He M, Sun H, Mao B. Placement of covered stents for the treatment of direct carotid cavernous fistulas. AJNR Am J Neuroradiol 2009;30:1342-6.
- 111. Willfort-Ehringer A, Ahmadi R, Gschwandtner ME, Haumer M, Lang W, Minar E. Single-center experience with carotid stent restenosis. J Endovasc Ther 2002;9:299-307.
- 112. Witz M, Gepstein R, Paran H, Shnaker A, Lehmann J, Gryton I, et al.. Endovascular treatment of an open cervical fracture with carotid artery tear. Eur Spine J 2006;15 Suppl 5:650-2.
- 113. Yi AC, Palmer E, Luh GY, Jacobson JP, Smith DC. Endovascular treatment of carotid and vertebral pseudoaneurysms with covered stents. AJNR Am J Neuroradiol 2008;29:983-7.
- 114. ZinglerVC, Strupp M, Brandt T, Herrmann K, Mayer TE. Stent grafting resolved brachial plexus neuropathy due to cervical arteriovenous fistula. Eur Neurol 2004;52:250-1.